The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Open accessAbstract
Chromosomal rearrangements have a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions. A recently discovered example is a fusion between the genes echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an inversion on the short arm of chromosome 2: inv(2)(p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) and is clinically relevant because it confers sensitivity to ALK inhibitors. Despite their importance, modelling such genetic events in mice has proven challenging and requires complex manipulation of the germ line. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumours invariably harbour the Eml4-Alk inversion, express the Eml4-Alk fusion gene, display histopathological and molecular features typical of ALK(+) human NSCLCs, and respond to treatment with ALK inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these events occur at low frequency, they could be significant in a clinical setting if rare translocations led to cancer 97-99 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [98]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus [52–55].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [55]
In the citing paper
“To establish disease models, in 2014, Maddalo et al. generated a model of non-small cell lung cancer by creating an Eml4 and Alk fusion gene through the intratracheal instillation of AdV-delivered CRISPR/Cas9 [35].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2291 · Cited by 896
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 633
CRISPR/Cas System and Factors Affecting Its Precision and Efficiency
Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 106
Young, C. S., Mokhonova, E. I., Quiñonez, M., Pyle, A. D., & Spencer, M. J. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-170218 · Cited by 96
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 104
CRISPR-directed mitotic recombination enables genetic mapping without crosses
Sadhu, M. J., Bloom, J. S., Day, L., & Kruglyak, L. (2016) · Science · doi:10.1126/science.aaf5124 · Cited by 103
Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling
Kirkpatrick, J. D., Warren, A., Soleimany, A. P., Westcott, P. M. K., Voog, J. C., Martin-Alonso, C., Fleming, H. E., Tammela, T., Jacks, T., & Bhatia, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0262 · Cited by 95
CRISPR/Cas systems: Delivery and application in gene therapy
Huang, J., Zhou, Y., Li, J., Lü, A., & Liang, C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.942325 · Cited by 102
Receptor tyrosine kinases: biological functions and anticancer targeted therapy
Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 97
A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence
Cheng, Y., Wang, S., Zhang, H., Lee, J.-S., Ni, C., Guo, J., Chen, E., Wang, S., Acharya, A., Chang, T.-C., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.019 · Cited by 92
piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice
Xu, C., Qi, X., Du, X., Zou, H., Gao, F., Feng, T., Lu, H., Li, S., An, X., Zhang, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615735114 · Cited by 91
Chromatin context-dependent regulation and epigenetic manipulation of prime editing
Li, X., Chen, W., Martin, B., Calderon, D., Lee, C., Choi, J., Chardon, F. M., McDiarmid, T. A., Daza, R. M., Kim, H., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.020 · Cited by 95
Cas9, Cpf1 and C2c1/2/3―What's next?
Nakade, S., Yamamoto, T., & Sakuma, T. (2017) · Bioengineered · doi:10.1080/21655979.2017.1282018 · Cited by 92
CRISPR/Cas9: Transcending the Reality of Genome Editing
Chira, S., Gulei, D., Hajitou, A., Zimța, A., Cordelier, P., & Berindan‐Neagoe, I. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.001 · Cited by 89
Hallmarks of cancer: The CRISPR generation
Moses, C., García‐Bloj, B., Harvey, A. R., & Blancafort, P. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.002 · Cited by 90
Lukhtanov, V. A., Dincă, V., Friberg, M., Šíchová, J., Olofsson, M., Vila, R., Marec, F., & Wiklund, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802610115 · Cited by 88
Genome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 86
ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
Zhang, Q., Xiao, M., Gu, S., Xu, Y., Liu, T., Li, H., Yu, Y., Qin, L. F., Zhu, Y., Chen, F., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0264-3 · Cited by 83
CRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 85
CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Liu, B., Saber, A., & Haisma, H. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.011 · Cited by 86
Song, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 81
Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 85
Brunet, E., & Jasin, M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0593-1_2 · Cited by 79
Zhang, W., Lypaczewski, P., & Matlashewski, G. (2017) · mSphere · doi:10.1128/msphere.00340-16 · Cited by 77
Applications of CRISPR Genome Engineering in Cell Biology
Wang, F., & Qi, L. S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.08.004 · Cited by 79
Ng, S. R., Rideout, W. M., Akama‐Garren, E. H., Bhutkar, A. J., Mercer, K. L., Schenkel, J. M., Bronson, R. T., & Jacks, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821893117 · Cited by 78
Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 79
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Ghosh, D., Venkataramani, P., Nandi, S., & Bhattacharjee, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0726-0 · Cited by 83
CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation
Wang, H., & Sun, W. Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.033 · Cited by 75
Huang, J., Chen, M., Whitley, M. J., Kuo, H.-C., Xu, E. S., Walens, A., Mowery, Y. M., Mater, D. V., Eward, W. C., Cardona, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15999 · Cited by 75
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
Oldrini, B., Curiel‐García, Á., Marques, C., Matía, V., Uluçkan, Ö., Graña‐Castro, O., Torres-Ruiz, R., Rodríguez, S., Huse, J. T., & Squatrito, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03731-w · Cited by 78
Cre-dependent Cas9-expressing pigs enable efficient in vivo genome editingPreprint
Wang, K., Jin, Q., Ruan, D., Yang, Y., Liu, Q., Wu, H., Zhou, Z., Ouyang, Z., Liu, Z., Zhao, Y., et al. (2017) · Genome Research · doi:10.1101/gr.222521.117 · Cited by 75
Lee, J., Ma, J., & Lee, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903230116 · Cited by 74
Dong, F., Xie, K., Chen, Y., Yang, Y., & Mao, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.129 · Cited by 75
Khosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 71
A versatile modular vector system for rapid combinatorial mammalian genetics
Albers, J., Danzer, C., Rechsteiner, M., Lehmann, H., Brandt, L. P., Hejhal, T., Catalano, A., Busenhart, P., Gonçalves, A. F., Brandt, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79743 · Cited by 73
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 73
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Strategies for In Vivo Genome Editing in Nondividing Cells
Nami, F., Basiri, M., Satarian, L., Curtiss, C., Baharvand, H., & Verfaillie, C. M. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.03.004 · Cited by 73
In situ cell-type-specific cell-surface proteomic profiling in mice
Shuster, S. A., Li, J., Chon, U., Sinantha-Hu, M. C., Luginbuhl, D. J., Udeshi, N. D., Carey, D. K., Takeo, Y. H., Xie, Q., Xu, C., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.025 · Cited by 70
Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis
Zhuang, X., Wang, Q., Joost, S., Ferrena, A., Humphreys, D. T., Li, Z., Blum, M., Krause, K., Ding, S., Landais, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-08285-0 · Cited by 71
Modeling human disease in rodents by CRISPR/Cas9 genome editing
Birling, M., Hérault, Y., & Pavlovic, G. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9703-x · Cited by 73
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症：英文版 · doi:10.1002/cac2.12366 · Cited by 69
A history of genome editing in mammals
Fernández, A., Josa, S., & Montoliu, L. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9699-2 · Cited by 68
Targeted genomic translocations and inversions generated using a paired prime editing strategy
Kweon, J., Hwang, H., Ryu, H., Jang, A.-H., Kim, D., & Kim, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.008 · Cited by 67
Designed nucleases for targeted genome editing
Lee, J., Chung, J., Kim, H. M., Kim, S., & Kim, S. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12465 · Cited by 70
Cook, P. J., Thomas, R., Kannan, R., León, E., Drilon, A. E. D. C., Rosenblum, M. K., Scaltriti, M., Benezra, R., & Ventura, A. (2017) · Nature Communications · doi:10.1038/ncomms15987 · Cited by 67
Self-citationDrug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
Katayama, R. (2018) · Cancer Science · doi:10.1111/cas.13504 · Cited by 66
CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms
Brunner, E., Yagi, R., Debrunner, M., Beck-Schneider, D., Burger, A., Escher, E., Mosimann, C., Hausmann, G., & Basler, K. (2019) · Life Science Alliance · doi:10.26508/lsa.201800267 · Cited by 65
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 65
Application of CRISPR/Cas9 genome editing to the study and treatment of disease
Pellagatti, A., Dolatshad, H., Valletta, S., & Boultwood, J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1504-y · Cited by 65
Applying CRISPR–Cas9 tools to identify and characterize transcriptional enhancers
Lopes, R., Korkmaz, G., & Agami, R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.79 · Cited by 65
Kim, H. S., Kweon, J., & Kim, Y. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01212-3 · Cited by 68
A versatile reporter system for CRISPR-mediated chromosomal rearrangements
Li, Y., Park, A. I., Mou, H., Colpan, C., Bizhanova, A., Akama‐Garren, E. H., Joshi, N., Hendrickson, E. A., Feldser, D. M., Yin, H., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0680-7 · Cited by 64
Strategies for Efficient Genome Editing Using CRISPR-Cas9
Farboud, B., Severson, A. F., & Meyer, B. J. (2018) · Genetics · doi:10.1534/genetics.118.301775 · Cited by 66
Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9
Torres-Ruiz, R., Martínez-Lage, M., Martin, M. C., Garcia, A., Bueno, C., Castaño, J., Ramı́rez, J. C., Menéndez, P. R., Cigudosa, J. C., & Rodríguez, S. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.014 · Cited by 66
Reshuffling yeast chromosomes with CRISPR/Cas9
Fleiss, A., O’Donnell, S., Fournier, T., Lü, W., Agier, N., Delmas, S., Schacherer, J., & Fischer, G. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008332 · Cited by 63
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Geusz, R. J., Wang, A., Lam, D. K., Vinckier, N. K., Alysandratos, K., Roberts, D. A., Wang, J., Kefalopoulou, S., Ramirez, A., Qiu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26950-0 · Cited by 61
Multiscale profiling of protease activity in cancer
Amini, A. P., Kirkpatrick, J. D., Wang, C. S., Jaeger, A. M., Su, S., Naranjo, S., Zhong, Q., Cabana, C. M., Jacks, T., & Bhatia, S. N. (2022) · Nature Communications · doi:10.1038/s41467-022-32988-5 · Cited by 60
Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer
Jiang, C., Lin, X., & Zhao, Z. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.007 · Cited by 61
Versatile single-step-assembly CRISPR/Cas9 vectors for dual gRNA expression
Adikusuma, F., Pfitzner, C., & Thomas, P. Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187236 · Cited by 58
CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
Herskovitz, J., Hasan, M., Patel, M., Blomberg, W. R., Cohen, J. D., Machhi, J., Stein, D., Schroder, E. A., McMillan, J., Gurumurthy, C. B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103678 · Cited by 63
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
Yang, X., & Zhang, B. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01117-w · Cited by 58
Connecting genotypes, phenotypes and fitness: harnessing the power of CRISPR /Cas9 genome editing
Bono, J. M., Olesnicky, E. C., & Matzkin, L. M. (2015) · Molecular Ecology · doi:10.1111/mec.13252 · Cited by 61
In vivo functional screening for systems-level integrative cancer genomics
Weber, J., Braun, C. J., Saur, D., & Rad, R. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0275-9 · Cited by 60
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 59
TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis
Li, J., Liang, C., Zhang, Z., Pan, X., Peng, S., Lee, W., Lü, A., Lin, Z., Zhang, G., Leung, W. N., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.23 · Cited by 57
Control of neural crest multipotency by Wnt signaling and the Lin28/let-7 axis
Bhattacharya, D., Rothstein, M., Azambujá, A. P., & Simões-Costa, M. (2018) · eLife · doi:10.7554/elife.40556 · Cited by 60
Sachdeva, M., Sachdeva, N., Pal, M., Gupta, N., Khan, I. A., Majumdar, M., & Tiwari, A. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.54 · Cited by 56
Vanoli, F., Tomishima, M. J., Feng, W., Lamribet, K., Babin, L., Brunet, E., & Jasin, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700622114 · Cited by 56
Acquisition of chromosome instability is a mechanism to evade oncogene addiction
Salgueiro, L., Buccitelli, C., Rowald, K., Somogyi, K., Kandala, S., Korbel, J. O., & Sotillo, R. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910941 · Cited by 58
Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020411 · Cited by 58
CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery
Luo, J. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.001 · Cited by 57
Cas9-expressing chickens and pigs as resources for genome editing in livestock
Rieblinger, B., Sid, H., Duda, D., Bozoglu, T. M., Klinger, R., Schlickenrieder, A., Lengyel, K., Flisikowski, K., Flisikowska, T., Simm, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022562118 · Cited by 59
Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 58
Genetically-engineered mouse models of small cell lung cancer: the next generation
Oser, M. G., MacPherson, D. P., Oliver, T. G., Sage, J., & Park, K.-S. (2024) · Oncogene · doi:10.1038/s41388-023-02929-7 · Cited by 54
Minimized combinatorial CRISPR screens identify genetic interactions in autophagy
Diehl, V., Wegner, M., Grumati, P., Husnjak, K., Schaubeck, S., Gubaš, A., Shah, V. J., Polat, I. H., Langschied, F., Prieto‐Garcia, C., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab309 · Cited by 55
Survival and Evolution of CRISPR–Cas System in Prokaryotes and Its Applications
Shabbir, M. A. B., Hao, H., Shabbir, M. Z., Hussain, H. I., Zahid, I., Ahmed, S., Sattar, A., Iqbal, M., Li, J., & Yuan, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00375 · Cited by 59
Towards quantitative and multiplexed in vivo functional cancer genomics
Winters, I. P., Murray, C. W., & Winslow, M. M. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0053-7 · Cited by 54
Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells
Bothmer, A., Gareau, K. W., Abdulkerim, H. S., Buquicchio, F. A., Cohen, L. A., Viswanathan, R., Zuris, J. A., Marco, E., Fernández, C. A., Myer, V. E., et al. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0074 · Cited by 56
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 53
From gene editing to genome engineering: restructuring plant chromosomes via CRISPR/Cas
Schmidt, C., Schindele, P., & Puchta, H. (2019) · aBIOTECH · doi:10.1007/s42994-019-00002-0 · Cited by 53
Next-Generation in vivo Modeling of Human Cancers
Gargiulo, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00429 · Cited by 55
High-Resolution In Vivo Identification of miRNA Targets by Halo-Enhanced Ago2 Pull-Down
Li, X., Pritykin, Y., Concepcion, C. P., Lu, Y., Rocca, G. L., Zhang, M., King, B., Cook, P. J., Au, Y. W., Popow, O., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.009 · Cited by 52
Self-citationTakeo, Y. H., Shuster, S. A., Jiang, L., Hu, M., Luginbuhl, D. J., Rülicke, T., Contreras, X., Hippenmeyer, S., Wagner, M. J., Ganguli, S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.11.028 · Cited by 56
Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy
Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.006 · Cited by 52
Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito, R., Kobayashi, T., Kashima, S., Matsumoto, K., & Ogawa, O. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01520-z · Cited by 53
Horvat, N. K., Chocarro, S., Marques, O., Bauer, T. A., Qiu, R., Diaz-Jimenez, A., Helm, B., Chen, Y., Sawall, S., Sparla, R., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c08335 · Cited by 51
CRISPR: a versatile tool for both forward and reverse genetics research
Gurumurthy, C. B., Grati, M., Ohtsuka, M., Schilit, S. L. P., Quadros, R. M., & Liu, X. Z. (2016) · Human Genetics · doi:10.1007/s00439-016-1704-4 · Cited by 52
CRISPR-Cas9: a promising genetic engineering approach in cancer research
Ratan, Z. A., Son, Y., Haidere, M. F., Uddin, B. M. M., Yusuf, M. A., Zaman, S. B., Kim, J., Banu, L. A., & Cho, J. Y. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834018755089 · Cited by 52
The Inescapable Influence of Noncoding RNAs in Cancer
Adams, B. D., Anastasiadou, E., Esteller, M., He, L., & Slack, F. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1989 · Cited by 48
Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery
Ahmad, G., & Amiji, M. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.014 · Cited by 48
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Mota, I. A., Patrucco, E., Mastini, C., Mahadevan, N. R., Thai, T. C., Bergaggio, E., Cheong, T.-C., Leonardi, G. C., Atabay, E. K., Campisi, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00591-2 · Cited by 47
Induction of site-specific chromosomal translocations in embryonic stem cells by CRISPR/Cas9
Jiang, J., Zhang, L., Zhou, X., Chen, X., Huang, G., Li, F., Wang, R., Wu, N. L., Yan, Y., Tong, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21918 · Cited by 48
CRISPR in Animals and Animal Models
Shrock, E., & Güell, M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 45
Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
Ciampricotti, M., Karakousi, T., Richards, A. L., Quintanal-Villalonga, À., Karatza, A., Caeser, R., Costa, E. A., Allaj, V., Manoj, P., Spainhower, K. B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0441 · Cited by 47
Self-citationRavichandran, M., & Maddalo, D. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1273994 · Cited by 47
Self-citationGenome-editing revolution: My whirlwind year with CRISPR
Doudna, J. A. (2015) · Nature · doi:10.1038/528469a · Cited by 50
Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 48
Neuwelt, A. J., Kimball, A. K., Johnson, A. M., Arnold, B. W., Bullock, B., Kaspar, R. E., Kleczko, E. K., Kwak, J., Wu, M., Heasley, L. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000441 · Cited by 46
Metadata
- Authors
- Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., Lowe, S. W., & Ventura, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Ospedaliera San Gerardo (IT)
- Corresponding author
- Ventura, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-10-22
- Volume
- 516
- Issue
- 7531
- Pages
- 423-427
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4270925
- OpenAlex
- W1972759536
- Cited by
- 640
- References
- 30
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 61 · 2021: 53 · 2020: 53 · 2019: 55 · 2018: 68 · 2017: 65 · 2016: 81 · 2015: 63 · 2014: 2
- FWCI
- 28.86
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-06-24)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, P01CA013106, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EML4-ALK fusion, chromosomal rearrangements, non-small cell lung cancer, somatic genome editing, tumor suppressor, oncogene cooperation
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Cells, Cultured, Disease Models, Animal, Genetic Engineering, Chromosome Inversion, Lung Neoplasms, Pyrazoles, Pyridines, Translocation, Genetic, Receptor Protein-Tyrosine Kinases, NIH 3T3 Cells, Protein Kinase Inhibitors, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
